FDA Will Keep Listening To Patient-Engagement Experts
Executive Summary
The US agency says in a 6 January Federal Register notice that it’s keeping its Patient Engagement Advisory Committee in place through October 2021 so it can gather more patient feedback that will come in handy when regulatory decisions need to be made. The committee, formed after the agency made a cultural shift to consider patient input on the types of products it allows on the market, was supposed to expire October 2019.
You may also be interested in...
FDA Patient Panel To Grapple With Recall Communications
The US FDA’s Patient Engagement Advisory Committee will discuss best practices for recall communications aimed at patients, as well as related topics, at an October forum.
FDA Meeting Will Focus On Aggregating Patient-Generated Health Data
The topic is central to the Patient Engagement Advisory Committee, which recently got its tenure extended. It also fits into the FDA’s thinking on real-world evidence and total product lifecycle approach.
Don't Take For Granted A Patient's Role In Clinical Trials, Experts Say
Catering to patients can help make clinical trials more accessible and useful, presenters argued at a recent conference.